A suspected plague death in Russia has triggered a 'fear trade' in vaccine stocks, particularly Novavax (NVAX), which saw a significant short squeeze. Despite the unconfirmed nature of the plague and Novavax's vaccine not being directly relevant to bacterial infections, the market reacted strongly to the pandemic-like headlines.
A suspected plague death at a Russian research institute, though unconfirmed and potentially misdiagnosed as pneumonia, sparked a 'fear trade' reminiscent of early pandemic days. This led to a significant rally in vaccine stocks, most notably Novavax (NVAX), which experienced a classic short squeeze due to its high short interest. The market reaction is driven by sentiment and short covering rather than fundamental changes, as Novavax's vaccine is not for bacterial infections like plague. The short-term implication is continued volatility based on news flow regarding the Russian situation, while the long-term impact is uncertain and dependent on actual confirmed cases and the development of relevant treatments/vaccines. Traders face an opportunity in momentum plays but also a risk of rapid reversals if the 'plague scare' dissipates.